BRCA1 and ovarian cancer: The F1CDx assay’s clinical efficacy was supported by bridging to the Foundation Focus CDxBRCA LOH assay in ovarian cancer patients with alterations in BRCA1, BRCA2, or demonstrated genomic loss of heterozygosity (gLOH).